Contact
 
News related to the Enterprise, its Stakeholders, and HIV Vaccine Research

Daily Dose of HIV Drug Reduces Risk of HIV Infection - NIAID Statement - November 23, 2010

The National Institutes of Health (NIH) issued a statement on the iPrEx study results, http://www.niaid.nih.gov/news/newsreleases/2010/Pages/iPrEx.aspx.   The statement quotes Anthony S.

Statement of Dr. Larry Corey on the Results of the iPrEx Study of HIV Prevention - November 23, 2010

The HVTN released a statement on the iPrEx study results, stating that "PrEP is an exciting addition to the “toolbox” of HIV prevention strategies."  The full statement is available below.

Evidence that daily antiretroviral pill reduces HIV risk in gay men - November 23, 2010

“This is a great day in the fight against AIDS. The positive results of the iPrEx oral PrEP study are a major milestone in HIV prevention research and provide important information about how antiretroviral drugs might be used for prevention byHIV-negative people at high risk for HIV infection,” said AVAC Executive Director Mitchell Warren. Click the below link to read the full statement.

Enterprise Applauds iPrEx Study Partners and Volunteers – Study adds to Most Promising Period in HIV Prevention Research Since Epidemic Began - November 23, 2010

The Global HIV Vaccine Enterprise released a statement today on the announcement of the results of the first study of oral pre-exposure prophylaxis (PrEP) for HIV prevention in humans.  "The iPrEx study, is a very important addition to what is the most promising 15 months in the field of HIV prevention research since the epidemic began 27 years ago."  The full statement is available below.

Enterprise Statement on the Resignation of Dr. Margaret Johnston from NIAID - November 11, 2010

The Council of the Global HIV Vaccine Enterprise issued the below statement today regarding the resignation of one of its founding members, Dr. Margaret (Peggy) Johnston, from the Vaccine Research Program at the U.S. National Institute of Allery and Infectious Diseases.

Grant Opportunity for Early Stage Investigators - November 11, 2010

The National Institute of Allergy and Infectious Diseases is funding a third round of the novel research initiative entitled “The Early Stage Investigator Scholar Award: Pilot Studies to Advance Non-Human Primate Models in Support of HIV Vaccine Clinical Research.”   For more details see www.hvtn.org/awards.   Interested applicants can submit a Letter of Intent to vtn.research@hvtn.org by 30 November 2010.  Full applications are due 5 January 2011.

New Lines of Attack in H.I.V. Prevention - November 9, 2010

The hottest news in AIDS in the last year was the partial success in a South African clinical trial of a microbicide.  Read the full New York Times article by Donald McNeil regarding the promise of microbicides upcoming PrEP results here.

New Study Shows Small Protein Changes Make Big Difference in Natural HIV Control - November 5, 2010

A new study published online in Science found that slight differences in the structure of a protein in the body that recognizes HIV could explain why some individuals infected with HIV are able to resist the onset of AIDS without treatment.  According to Dr.

AVAC Publications and Web site Survey - November 4, 2010

AVAC: Global Advocacy for HIV Prevention is seeking feedback to better understand how their materials and website are used and how they can be improved. AVAC asks advocates to complete the AVAC publications and web site survey here. The survey should take no more than 10-15 minutes to complete.

Sixth EDCTP Forum: opening of registration and call for abstracts - November 2, 2010

The theme of the forum is Strengthening Research Partnerships for Better Health and Sustainable Development, taking into account the past, present and future of EDCTP. For more information, click here.

Syndicate content
Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account